Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

12.1.22

Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

11.9.22

Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

11.4.22

Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

10.26.22

Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022

10.11.22

Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference

09.7.22

Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

08.12.22

Terns Announces $65 Million Oversubscribed Offering

08.8.22

Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

07.27.22

Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

06.22.22

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

Pagination

Current page 1
Page 2
Next page
Last page

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4254

Site - Social

Site - Corporate

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2022 Terns Pharmaceuticals, Inc. Privacy Policy